Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nagaraj Velugonda"'
Autor:
Meher Bolisetti Gayatri, Rama Krishna Kancha, Abhayananda Behera, Dorababu Patchva, Nagaraj Velugonda, Sadasivudu Gundeti, Aramati Bindu Madhava Reddy
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Imatinib resistance remains an unresolved problem in CML disease. Activation of JAK2/STAT3 pathway and increased expression of RUNX1 have become one reason for development of imatinib resistance in CML subjects. Metformin has gained attentio
Externí odkaz:
https://doaj.org/article/3d3b4f3397d24ba483df1239aecf2893
Autor:
Meher Bolisetti Gayatri, Rama Krishna Kancha, Dorababu Patchva, Nagaraj Velugonda, Sadashivudu Gundeti, Aramati B. M. Reddy
Publikováno v:
The FEBS Journal.
Autor:
Ramya Lakshmi Veduruvada, Megha S. Uppin, Meher Lakshmi Konatam, Rajesh Alugolu, Vamsi Krishna Yeramneni, Suchanda Bhattacharjee, Mudumba Vijaya Saradhi, Monica Malik Irukulla, Madhumohan Rao, Nagaraj Velugonda
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 42:569-576
Introduction Astrocytomas are the most common gliomas, classified on the basis of grade and IDH mutation status according to the World Health Organization (WHO) 2016 update. IDH mutations are seen in 70 to 80% of diffuse grade II and III astrocytomas